Ankara Bilkent City Hospital is a full-service city hospital located in Ankara, Turkey. Opened in 2019, it is the biggest in the country having a total of 3,704 hospital beds.

There are 3,704 beds in Ankara Sehir Hastanesi.

During the past decade, Ankara Sehir Hastanesi conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ankara Sehir Hastanesi" #1 sponsor was "Amgen" with 4 trials, followed by "Bayer" with 4 trials sponsored, "Actelion" with 2 trials sponsored, "Ankara City Hospital Bilkent" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ankara Sehir Hastanesi" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator, "Innovative Medicines Initiative (IMI) COMBACTE-CARE (EU)" with 1 trials as a collaborator, "Innovative Therapies For Children with Cancer Consortium" with 1 trials as a collaborator and "Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Ankara Sehir Hastanesi" are "Acute Lymphoblastic Leukemia (ALL)" (1 trials), "Atherosclerotic Cardiovascular Disease" (1 trials), "Atrial Fibrillation" (1 trials), "Carcinoma, Non-squamous Non-small-cell Lung" (1 trials) and "Carcinoma, Squamous Cell, Non-small-cell Lung" (1 trials). Many other conditions were trialed in "Ankara Sehir Hastanesi" in a lesser frequency.

Most popular intervention types in "Ankara Sehir Hastanesi" are "Drug" (17 trials), "Biological" (4 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Carboplatin" (2 trials), "Olaparib" (2 trials), "Pembrolizumab" (2 trials) and "6-Mercaptopurine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ankara Sehir Hastanesi" are 20 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Ankara Sehir Hastanesi". undefined are not yet recruiting, 11 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Ankara Sehir Hastanesi, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Ankara Sehir Hastanesi, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".